Integer Announces CEO Succession Plan
Integer Holdings (NYSE: ITGR) announced a leadership transition as Joseph Dziedzic plans to retire as President and CEO effective October 24, 2025. Payman Khales, current Chief Operating Officer, will succeed as President and CEO and join the Board of Directors.
Under Dziedzic's eight-year tenure, Integer focused on high-growth markets, enhanced investment in differentiated technologies, and implemented the Integer Production System. Khales, who joined in 2018 as President of Cardio & Vascular business, has demonstrated strong leadership by doubling the division's sales in seven years and achieving above-market growth. As COO, he currently oversees both Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation business units.
To ensure a smooth transition, Dziedzic will serve as an advisor through March 31, 2026.
Integer Holdings (NYSE: ITGR) ha annunciato un cambio di leadership: Joseph Dziedzic si ritirerà dalla carica di Presidente e CEO a partire dal 24 ottobre 2025. Payman Khales, attuale Chief Operating Officer, gli succederà come Presidente e CEO e entrerà a far parte del Consiglio di Amministrazione.
Durante gli otto anni di guida di Dziedzic, Integer si è concentrata su mercati ad alta crescita, ha aumentato gli investimenti in tecnologie differenziate e ha implementato il Sistema di Produzione Integer. Khales, entrato nel 2018 come Presidente della divisione Cardio & Vascular, ha dimostrato una leadership solida raddoppiando le vendite della divisione in sette anni e ottenendo una crescita superiore al mercato. Come COO, attualmente supervisiona sia le unità di business Cardio & Vascular che Cardiac Rhythm Management & Neuromodulation.
Per garantire una transizione fluida, Dziedzic resterà in qualità di consulente fino al 31 marzo 2026.
Integer Holdings (NYSE: ITGR) anunció una transición en su liderazgo: Joseph Dziedzic planea retirarse como Presidente y CEO a partir del 24 de octubre de 2025. Payman Khales, actual Director de Operaciones, lo sucederá como Presidente y CEO y se unirá al Consejo de Administración.
Bajo el mandato de ocho años de Dziedzic, Integer se enfocó en mercados de alto crecimiento, aumentó la inversión en tecnologías diferenciadas e implementó el Sistema de Producción Integer. Khales, quien se unió en 2018 como Presidente del negocio de Cardio & Vascular, ha demostrado un liderazgo sólido al duplicar las ventas de la división en siete años y lograr un crecimiento superior al del mercado. Como COO, actualmente supervisa las unidades de negocio de Cardio & Vascular y Cardiac Rhythm Management & Neuromodulation.
Para asegurar una transición sin contratiempos, Dziedzic actuará como asesor hasta el 31 de marzo de 2026.
Integer Holdings (NYSE: ITGR)는 리더십 변화를 발표했습니다. Joseph Dziedzic는 2025년 10월 24일부로 사장 겸 CEO에서 은퇴할 예정입니다. 현재 최고운영책임자인 Payman Khales가 사장 겸 CEO로 승계하며 이사회에 합류할 예정입니다.
Dziedzic가 8년간 재임하는 동안 Integer는 고성장 시장에 집중하고 차별화된 기술에 대한 투자를 강화했으며 Integer 생산 시스템을 도입했습니다. 2018년에 Cardio & Vascular 사업부 사장으로 합류한 Khales는 7년 동안 사업부 매출을 두 배로 늘리고 시장 평균 이상의 성장을 달성하는 강력한 리더십을 보여주었습니다. COO로서 현재는 Cardio & Vascular와 Cardiac Rhythm Management & Neuromodulation 사업부를 총괄하고 있습니다.
원활한 인수인계를 위해 Dziedzic는 2026년 3월 31일까지 고문으로 활동할 예정입니다.
Integer Holdings (NYSE: ITGR) a annoncé une transition à la tête de l’entreprise : Joseph Dziedzic prévoit de prendre sa retraite en tant que Président et CEO à compter du 24 octobre 2025. Payman Khales, actuel Directeur des opérations, lui succédera en tant que Président et CEO et rejoindra le Conseil d'administration.
Durant les huit années de mandat de Dziedzic, Integer s’est concentrée sur des marchés à forte croissance, a accru ses investissements dans des technologies différenciées et a mis en œuvre le Système de Production Integer. Khales, qui a rejoint l’entreprise en 2018 en tant que Président de la division Cardio & Vascular, a démontré un leadership solide en doublant les ventes de cette division en sept ans et en réalisant une croissance supérieure à celle du marché. En tant que COO, il supervise actuellement les unités commerciales Cardio & Vascular ainsi que Cardiac Rhythm Management & Neuromodulation.
Pour assurer une transition en douceur, Dziedzic restera conseiller jusqu’au 31 mars 2026.
Integer Holdings (NYSE: ITGR) gab einen Führungswechsel bekannt: Joseph Dziedzic plant, zum 24. Oktober 2025 als Präsident und CEO in den Ruhestand zu treten. Payman Khales, der derzeitige Chief Operating Officer, wird seine Nachfolge als Präsident und CEO antreten und dem Vorstand beitreten.
Während Dziedzics achtjähriger Amtszeit konzentrierte sich Integer auf wachstumsstarke Märkte, steigerte Investitionen in differenzierte Technologien und implementierte das Integer Production System. Khales, der 2018 als Präsident der Cardio & Vascular-Sparte begann, zeigte starke Führungskompetenz, indem er den Umsatz der Division in sieben Jahren verdoppelte und ein über dem Marktdurchschnitt liegendes Wachstum erzielte. Als COO verantwortet er derzeit sowohl die Geschäftsbereiche Cardio & Vascular als auch Cardiac Rhythm Management & Neuromodulation.
Um einen reibungslosen Übergang zu gewährleisten, wird Dziedzic bis zum 31. März 2026 als Berater tätig sein.
- Doubled Cardio & Vascular division sales in seven years under Khales' leadership
- Above-market organic sales growth with expanding margins
- Strong momentum in business development and differentiated capabilities
- None.
Insights
Integer's well-executed CEO succession plan signals leadership continuity with an experienced internal candidate during a period of described strong performance.
Integer Holdings has announced a structured CEO succession plan with current CEO Joseph Dziedzic retiring after eight years, to be succeeded by COO Payman Khales effective October 24, 2025. This represents a carefully orchestrated leadership transition with Dziedzic remaining as an advisor through March 31, 2026, providing a six-month transition period that suggests organizational stability.
The succession follows corporate governance best practices with a qualified internal candidate who has demonstrated measurable success. Khales's track record is particularly impressive - since joining in 2018 as President of the Cardio & Vascular business, he doubled sales in seven years while achieving above-market growth with improved service levels and profitability. His subsequent promotion to COO gave him oversight of both business units along with global operations and manufacturing strategy, indicating thorough preparation for the CEO role.
The board's comments suggest satisfaction with the company's current trajectory, noting Integer is "delivering on its financial objectives of above market organic sales growth with expanding margins." This indicates the leadership transition occurs during a period of positive performance, rather than during a challenging situation.
For medical device contract manufacturers like Integer, leadership continuity and operational excellence are particularly valued by customers who depend on consistent quality and supply chain reliability. The "Integer Production System" implemented under Dziedzic represents a focus on manufacturing consistency that aligns with Khales's operational background.
The six-month advance notice provides stakeholders with appropriate time to adjust and allows for a managed handover of responsibilities, further suggesting this represents continuity rather than a strategic pivot.
~ Joseph Dziedzic to retire as President and CEO ~
~ Payman Khales appointed President and CEO effective October 24, 2025 ~
PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization, today announced that Joseph Dziedzic will retire as President and Chief Executive Officer and will step down from the Board of Directors, effective October 24, 2025. At that time, Payman Khales, Chief Operating Officer, will assume the President and CEO position and join the Company’s Board. To ensure a smooth transition, Mr. Dziedzic will serve as an advisor to the Company through March 31, 2026.
“We are incredibly grateful to Joe, whose vision, strategy, and ability to create a high-performance culture has driven Integer’s significant growth and value creation during his eight-year tenure as CEO,” said Pamela G. Bailey, Chair of the Board. “Among many other accomplishments, Joe reshaped Integer’s business to focus on high growth markets that address unmet patient needs, accelerated organic and inorganic investment in differentiated technologies, and developed and implemented the Integer Production System to create consistency across our manufacturing operations. Integer is delivering on its financial objectives of above market organic sales growth with expanding margins and is well positioned to continue this growth trajectory. We wish him the very best in a well-deserved retirement.”
“It has been an honor to lead the Integer team through this pivotal period in our Company’s history, and I am proud of what we have accomplished for our customers and patients around the world,” said Mr. Dziedzic. “Payman is the natural choice to guide Integer through our next chapter of growth. He is an exceptional leader who embodies our commitment to innovation, quality and operational excellence, and his track record speaks for itself. Payman has been an integral part of the development and execution of our strategy, both within Cardio & Vascular and across the enterprise, while leading Integer’s Customer Operational Strategic Imperatives. I look forward to the Company’s continued success under Payman’s leadership.”
Mr. Khales joined Integer in 2018 as President of the Cardio & Vascular business. Under his leadership, the business established a successful market/customer-based strategy, doubling sales in seven years, accelerating market penetration, and achieving above-market growth, while improving service levels and profitability. Since becoming COO, he has overseen both of Integer’s business units, Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation, along with global operations and manufacturing strategy.
“I am honored to be named the next CEO of Integer and would like to thank Joe and the Board of Directors for having faith in me to lead this amazing company in its next chapter,” said Mr. Khales. “I am excited about the strong momentum in our business as we continue to build differentiated capabilities and collaborate closely with our customers to deliver innovative medical device technologies to patients around the globe. I thank Joe for his mentorship over the past seven years and continued support in the coming months as we prepare to transition. He set the vision and strategy that transformed Integer into the strong company it is today, and I wish him a very enjoyable retirement later this year.”
First Quarter 2025 Results
In a separate press release issued today, Integer reported first quarter 2025 financial results. The Company will host a conference call today at 8 a.m. CT / 9 a.m. ET to discuss these results.
That press release, along with other investor materials, including a slide presentation and reconciliations of certain non-GAAP measures to their nearest GAAP measures, will also be available on investor.integer.net.
About Payman Khales
Mr. Khales currently serves as COO of Integer, and previously served as President of the Cardio & Vascular product category since 2018.
Prior to joining Integer, Mr. Khales served as President of the Environmental Technologies business segment for CECO Environmental Corp., a diversified global provider of engineered technologies to the environmental, energy, and fluid handling and filtration industrial segments. He also held several progressive leadership roles at Ingersoll Rand Company.
Mr. Khales holds an Executive Master of Business Administration from Indiana University’s Kelley School of Business, and a Bachelor of Science in Mechanical Engineering from École Polytechnique de Montréal.
About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: |
| Kristen Stewart | Kelly Butler |
| kristen.stewart@integer.net | kelly.butler@integer.net |
| 551.337.3973 | 469.731.6617 |
FAQ
When will Integer Holdings (ITGR) CEO Joseph Dziedzic retire?
Who will be the new CEO of Integer Holdings (ITGR)?
What were Payman Khales' achievements at Integer Holdings (ITGR)?
How long will Joseph Dziedzic serve as advisor after stepping down as ITGR CEO?
